AI-ACCELERATED DRUG DISCOVERY
Available from Reaxense
This protein is integrated into the Receptor.AI ecosystem as a prospective target with high therapeutic potential. We performed a comprehensive characterization of Interleukin-17 receptor D including:
1. LLM-powered literature research
Our custom-tailored LLM extracted and formalized all relevant information about the protein from a large set of structured and unstructured data sources and stored it in the form of a Knowledge Graph. This comprehensive analysis allowed us to gain insight into Interleukin-17 receptor D therapeutic significance, existing small molecule ligands, relevant off-targets, and protein-protein interactions.
Fig. 1. Preliminary target research workflow
2. AI-Driven Conformational Ensemble Generation
Starting from the initial protein structure, we employed advanced AI algorithms to predict alternative functional states of Interleukin-17 receptor D, including large-scale conformational changes along "soft" collective coordinates. Through molecular simulations with AI-enhanced sampling and trajectory clustering, we explored the broad conformational space of the protein and identified its representative structures. Utilizing diffusion-based AI models and active learning AutoML, we generated a statistically robust ensemble of equilibrium protein conformations that capture the receptor's full dynamic behavior, providing a robust foundation for accurate structure-based drug design.
Fig. 2. AI-powered molecular dynamics simulations workflow
3. Binding pockets identification and characterization
We employed the AI-based pocket prediction module to discover orthosteric, allosteric, hidden, and cryptic binding pockets on the protein’s surface. Our technique integrates the LLM-driven literature search and structure-aware ensemble-based pocket detection algorithm that utilizes previously established protein dynamics. Tentative pockets are then subject to AI scoring and ranking with simultaneous detection of false positives. In the final step, the AI model assesses the druggability of each pocket enabling a comprehensive selection of the most promising pockets for further targeting.
Fig. 3. AI-based binding pocket detection workflow
4. AI-Powered Virtual Screening
Our ecosystem is equipped to perform AI-driven virtual screening on Interleukin-17 receptor D. With access to a vast chemical space and cutting-edge AI docking algorithms, we can rapidly and reliably predict the most promising, novel, diverse, potent, and safe small molecule ligands of Interleukin-17 receptor D. This approach allows us to achieve an excellent hit rate and to identify compounds ready for advanced lead discovery and optimization.
Fig. 4. The screening workflow of Receptor.AI
Receptor.AI, in partnership with Reaxense, developed a next-generation technology for on-demand focused library design to enable extensive target exploration.
The focused library for Interleukin-17 receptor D includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Interleukin-17 receptor D
partner:
Reaxense
upacc:
Q8NFM7
UPID:
I17RD_HUMAN
Alternative names:
IL17Rhom; Interleukin-17 receptor-like protein; Sef homolog
Alternative UPACC:
Q8NFM7; Q2NKP7; Q58EZ7; Q6RVF4; Q6UWI5; Q8N113; Q8NFS0; Q9UFA0
Background:
Interleukin-17 receptor D (IL17RD), also known as Sef homolog and IL17Rhom, plays a critical role in regulating several signaling pathways. It acts as a feedback inhibitor of fibroblast growth factor (FGF) mediated Ras-MAPK signaling and ERK activation. IL17RD regulates nuclear ERK signaling by preventing the nuclear translocation of activated ERK. Additionally, it may mediate JNK activation and influence apoptosis, inhibit FGF-induced FGFR1 tyrosine phosphorylation, and play a role in the specification of GnRH-secreting neurons.
Therapeutic significance:
IL17RD's involvement in Hypogonadotropic hypogonadism 18 with or without anosmia highlights its potential as a therapeutic target. Understanding the role of IL17RD could open doors to potential therapeutic strategies for treating this disorder, which is characterized by low levels of circulating gonadotropins and testosterone, and in some cases, anosmia, cleft palate, and sensorineural hearing loss.
